BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12775136)

  • 21. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma.
    Schuh S; Dick PT; Stephens D; Hartley M; Khaikin S; Rodrigues L; Coates AL
    Pediatrics; 2006 Aug; 118(2):644-50. PubMed ID: 16882819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma.
    Stempel DA; Riedel AA; Carranza Rosenzweig JR
    Curr Med Res Opin; 2006 Mar; 22(3):463-70. PubMed ID: 16574030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study.
    Dupont L; Potvin E; Korn D; Lachman A; Dramaix M; Gusman J; Peché R;
    Curr Med Res Opin; 2005 Jun; 21(6):863-9. PubMed ID: 15969886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years.
    Nelson KA; Smith SR; Trinkaus K; Jaffe DM
    Pediatr Emerg Care; 2008 Jan; 24(1):21-7. PubMed ID: 18165796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination].
    Grosclaude M; Cerruti JL; Delannay B; Hérent M; Spilthooren F; Desfougères JL
    Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):356-62. PubMed ID: 14716965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast.
    Jayaram L; Pizzichini E; Lemière C; Man SF; Cartier A; Hargreave FE; Pizzichini MM
    Thorax; 2005 Feb; 60(2):100-5. PubMed ID: 15681495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
    Nelson HS; Busse WW; Kerwin E; Church N; Emmett A; Rickard K; Knobil K
    J Allergy Clin Immunol; 2000 Dec; 106(6):1088-95. PubMed ID: 11112891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS; Eid NS; Crespi S; Wilcox TK; Reardon G
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
    Delea TE; Hagiwara M; Stanford RH; Stempel DA
    Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral montelukast treatment of preschool-aged children with acute asthma.
    Harmanci K; Bakirtas A; Turktas I; Degim T
    Ann Allergy Asthma Immunol; 2006 May; 96(5):731-5. PubMed ID: 16729788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.
    Bleecker ER; Yancey SW; Baitinger LA; Edwards LD; Klotsman M; Anderson WH; Dorinsky PM
    J Allergy Clin Immunol; 2006 Oct; 118(4):809-16. PubMed ID: 17030231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma.
    Szefler SJ; Baker JW; Uryniak T; Goldman M; Silkoff PE
    J Allergy Clin Immunol; 2007 Nov; 120(5):1043-50. PubMed ID: 17983871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
    Orsini L; Limpa-Amara S; Crown WH; Stanford RH; Kamal K
    Ann Allergy Asthma Immunol; 2004 May; 92(5):523-9. PubMed ID: 15191020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
    Baumgarten C; Geldszus R; Behre U; Peslis N; Trautmann M;
    Eur J Med Res; 2002 Jan; 7(1):1-7. PubMed ID: 11827834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Montelukast improves pulmonary function measured by impulse oscillometry in children with asthma (Mio study).
    Nieto A; Pamies R; Oliver F; Medina A; Caballero L; Mazon A
    Respir Med; 2006 Jul; 100(7):1180-5. PubMed ID: 16330196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of 3-5 months' add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational study.
    Schlick W; Pohl W; Pfeiffer KP; Aigner K; Forche G; Kneussl M; Zwick H
    Curr Med Res Opin; 2010 Mar; 26(3):561-70. PubMed ID: 20050815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asthma-related health care resource use among patients starting fluticasone or montelukast therapy.
    Allen-Ramey FC; Anstatt DT; Sajjan SG; Markson LE
    Pharmacotherapy; 2005 Dec; 25(12):1752-60. PubMed ID: 16305295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma.
    Davies GM; Dasbach EJ; Santanello NC; Knorr BA; Bratton DL
    Clin Ther; 2004 Nov; 26(11):1895-904. PubMed ID: 15639701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.